Get started
Author

Monique Klaver

Observed name: M. Klaver
Observed institution: Astellas Pharma (Netherlands)
ORCID: 0000-0003-4464-1304
Observed ORCID: 0000-0003-4464-1304
OpenAlex ID: A5009422584
Combination Therapy with Solifenacin and Tamsulosin Oral Controlled Absorption System in a Single Tablet for Lower Urinary Tract Symptoms in Men: Efficacy and Safety Results from the Randomised Controlled NEPTUNE Trial
2013 · Philip van Kerrebroeck, Christopher Chapple, et al. · European Urology · 106
Qualitative Exploration of the Patient Experience of Underactive Bladder
2017 · Alan D. Uren, Nikki Cotterill, et al. · European Urology · 81
Long-term Safety and Efficacy of Single-tablet Combinations of Solifenacin and Tamsulosin Oral Controlled Absorption System in Men with Storage and Voiding Lower Urinary Tract Symptoms: Results from the NEPTUNE Study and NEPTUNE II Open-label Extension
2014 · Marcus J. Drake, Christopher Chapple, et al. · European Urology · 81
Efficacy and Safety of Solifenacin Plus Tamsulosin OCAS in Men with Voiding and Storage Lower Urinary Tract Symptoms: Results from a Phase 2, Dose-finding Study (SATURN)
2013 · Philip Van Kerrebroeck, François Haab, et al. · European Urology · 78
Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms
2013 · Christopher R. Chapple, Marcus J. Drake, et al. · British Journal of Urology · 38
Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies
2017 · Marcus J. Drake, Matthias Oelke, et al. · PLoS ONE · 27
PDF
Responder and health‐related quality of life analyses in men with lower urinary tract symptoms treated with a fixed‐dose combination of solifenacin and tamsulosin oral‐controlled absorption system: results from the NEPTUNE study
2015 · Marcus J. Drake, Roman Sokol, et al. · British Journal of Urology · 19
Validation of the Patient Perception of Intensity of Urgency Scale in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
2014 · Susan D. Mathias, Ross D. Crosby, et al. · Value in Health · 12
PDF
The development of the ICIQ‐UAB: A patient reported outcome measure for underactive bladder
2019 · Alan D. Uren, Nikki Cotterill, et al. · Neurourology and Urodynamics · 11
1089 Quality of life analyses from NEPTUNE, a phase 3 trial of combination therapy with tamsulosin OCAS™ and solifenacin in men with lower urinary tract symptoms
2013 · M.J. Drake, R. Sokol, et al. · European Urology Supplements · 4
327 Effects of Tamsulosin Ocas™ and Solifenacin on Efficacy and Qol Parameters in Men With Luts/bph in the Saturn Trial
2011 · P.E.V. Van Kerrebroeck, M. Oelke, et al. · European Urology Supplements · 4
746 Efficacy of combination therapy with tamsulosin OCAS™ and solifenacin in NEPTUNE: Results from a randomised, phase 3 trial in men with LUTS
2012 · M. Drake, C. Chapple, et al. · European Urology Supplements · 3
MP-05.01 Evaluating the Efficacy and Safety of Fixed-Dose Combinations of Tamsulosin OCAS™ and Solifenacin in Male LUTS with Storage and Voiding Symptoms: An Overview of the NEPTUNE Trial
2011 · M. Drake, M. Speakman, et al. · Urology · 3
MP-05.02 Combination Therapy with Tamsulosin OCAS™ and Solifenacin is more Effective than Solifenacin Monotherapy as a Treatment for Male LUTS Associated with BPH: Results from the SATURN Trial
2011 · J. Wyndaele, A.R. Cicalese, et al. · Urology · 3
MP-05.03 The Effects of Tamsulosin OCAS™ Plus Solifenacin on Quality of Life (QoL) Parameters in Men with LUTS Associated with BPH Participating in the SATURN Trial
2011 · P. van Kerrebroeck, J. Krhut, et al. · Urology · 2
UP-02.014 Safety of Tamsulosin OCAS™ plus Solifenacin in Men with LUTS Associated with BPH in the SATURN Trial
2011 · F. Haab, P. van Kerrebroeck, et al. · Urology · 2
MP-01.10: Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN)
2010 · P. Van Kerrebroeck, M. Oelke, et al. · Urology · 2
Qualitative development of a new patient reported outcome measure for underactive bladder
2016 · Alan Uren, Nikki Cotterill, et al. · UWE Research Repository (UWE Bristol) · 1
995 The patient experience of underactive bladder
2016 · A. Uren, N. Cotterill, et al. · European Urology Supplements · 1
The patient perception of intensity of urgency scale (PPIUS): Its validation in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)
2013 · S.D. Mathias, R. Crosby, et al. · Value in Health · 1
PDF
Reply to Bora Lee and Jae Heon Kim's Letter to the Editor re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402–7
2017 · Alan D. Uren, Nikki Cotterill, et al. · European Urology
Reply from Authors re: Mikkel Fode, Jens Sønksen. Towards a Greater Understanding of Underactive Bladder. Eur Urol 2017;72:408–9
2017 · Alan D. Uren, Nikki Cotterill, et al. · European Urology
Pilot assessment of the psychometric properties of the ICIQ-UAB patient reported outcome instrument in patients with detrusor underactivity
2017 · Alan Uren, Nikki Cotterill, et al. · Research Publications (Maastricht University)
772 Patient satisfaction with the safety and efficacy of fixed-dose combinations of solifenacin and tamsulosin OCAS™: Results from the NEPTUNE II study
2014 · M.J. Drake, C. Chapple, et al. · European Urology Supplements
Reply from Authors re: Apostolos Apostolidis. Male Lower Urinary Tract Symptoms: A Riddle Waiting to Be Solved. Eur Urol 2013;64:408–10
2013 · Philip Van Kerrebroeck, François Haab, et al. · European Urology
Works count: 26
Citation count: 479
H-index: 9
I10-index: 9
Year
Topic
Type